METEOR, a phase 3 clinical trial, compared cabozantinib with everolimus for the treatment of patients with advanced clear cell renal cell carcinoma. Analysis of the results in July 2015 showed that the estimated median progression-free survival time for patients in the trial, randomised to receive cabozantinib, was 7.4 months, whereas it was 3.8 months for those receiving everolimus. The objective response rate, assessed up to 17 months, was 21% for cabozantinib and 5% for everolimus.
Presented at the European Cancer Conference (ECC) 2015 by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA.
